¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇÑÁö¹æ°£¿¬±¸È¸ KNSG NAFLD Symposium 2023: Multidisciplinary Approach We Go Together : 2023-10-14

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

´ëÇÑÁö¹æ°£¿¬±¸È¸ KNSG NAFLD Symposium 2023: Multidisciplinary Approach We Go Together : 2023-10-14
±³À°ÀÏÀÚ : 2023-10-14
±³À°Àå¼Ò : ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ 1Ãþ À¯ÀÏÇÑȦ

±³À°ÁÖÁ¦ : KNSG NAFLD Symposium 2023: Multidisciplinary Approach We Go Together

ÁÖÃÖ±â°ü : ´ëÇÑ°£ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇÑÁö¹æ°£¿¬±¸È¸

´ã´çÀÚ : ´ëÇÑ°£ÇÐȸ
¿¬¶ôó : 02-707-0091

À̸ÞÀÏ : kasl@kams.or.kr

±³À°Á¾·ù : ³»°ú

Âü¼®¿¹»óÀÎ : 200¸í
Èñ¸ÁÆòÁ¡ : 5Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 20ºÐ

¼¼ºÎ¼ö°­·á : 50,000¿ø  

ºñ°í "»çÀüµî·Ï-ȸ¿ø,ÀüÀÓÀÇ,Àü°øÀÇ 3¸¸¿ø

ºñȸ¿ø,¿Â¶óÀÎȸ¿ø 4¸¸¿ø 

ÇöÀåµî·Ï-ȸ¿ø,ÀüÀÓÀÇ,Àü°øÀÇ 4¸¸¿ø 

ºñȸ¿ø,¿Â¶óÀÎȸ¿ø 5¸¸¿ø"  


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 09:15~09:35 NAFLD and type 2 diabetes ÇÑÀ¯Áø(°è¸íÀÇ´ë)

±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 09:35~09:55 NAFLD and chronic kidney disease Á¤Âù¿µ(¿ï»êÀÇ´ë)

±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 09:55~10:15 Identification of NAFLD patients with high-risk CVD ÀÌÂùÁÖ(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 10:15~10:35 NAFLD and obesity: Medical perspective Alice PS KONG(CUHK)

±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 10:45~11:05 Sex-dependent NAFLD progression Ayako Suzuki(Duke University)

±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 11:05~11:25 Cognitive and behavioral impairments related to NASH Somaya Albhaisi(Virginia Commonwealth University)

±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 11:25~11:45 Role of hepatocyte Kctd17 in glucose tolerance and hepatic steatosis ±è°æÁø(ÀÎÇÏÀÇ´ë)

±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 11:45~12:05 Tcf7l2 in hepatocytes regulates de novo lipogenesis in NAFLD ¿À°æÁø(KRIBB)

±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 12:05~12:25 Roles of portal lipoprotein and immunity as guardians of the liver ÇÑ¿ëÇö(°­¿ø¾à´ë)

±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 13:25~13:45 Barriers for successful clinical trials in NASH Stephen A Harrison(Pinnacle Clinical Research, San Antonio)

±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 13:45~14:05 Biomarkers for identifying at-risk NASH and monitoring treatment response ±è¿ø(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 14:05~14:25 Pharmacotherapeutics in phase II and III clinical trial ¹Ú¼ö¿µ(°æºÏÀÇ´ë)

±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 14:35~14:55 Different diets, different outcomes °íÇýÁø(°æºÏÀÇ´ë)

±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 14:55~15:15 What types of exercise are beneficial for NAFLD/NASH? ¹ÚÁøÈ£(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 15:15~15:35 The potential of 3D food printing technology for application to patients with metabolic diseases ±èÀº°æ(µ¿¾Æ´ëÇб³)

±³À°½Ã°£ 10¿ù 14ÀÏ ½ÅÃ̼¼ºê¶õ½ºº´¿ø ¿¡ºñ½¼ÀÇ»ý¸í¿¬±¸¼¾ÅÍ À¯ÀÏÇÑȦ 15:35~15:55 Novel therapeutic targets in NAFLD treatment in the year of 2023 Àü´ë¿ø(ÇѾçÀÇ´ë)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇÑÁö¹æ°£¿¬±¸È¸ KNSG NAFLD Symposium 2023: Multidisciplinary Approach We Go Together : 2023-10-14""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇÑÁßȯÀÚÀÇÇÐȸ (¿Â¶óÀÎ) The 14th SCCM¡¯s Multiprofessional Critical Care Review Course in Seoul, 2023 (MCCRC 2023) (2ÀÏÂ÷) : 2023-10-14
´ÙÀ½±Û 2023³â ´ëÇѽÅÀåÇÐȸ ÀüÇØÁú°íÇ÷¾Ð¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2023-10-14
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20589 ¼­¿ï ´ëÇÑÁ¾¾ç³»°úÇÐȸ Recent updates in GI Cancer 2024 : 2024-06-14 0 62 2024-04-29
20588 ¼­¿ï ´ëÇÑ°ñ´ë»çÇÐȸ SSBH 2024 (The 12th Seoul Symposium on Bone Health)&Á¦36Â÷ Ãá°èÇмú´ëȸ 2ÀÏÂ÷ : 2024-06-14 0 60 2024-04-29
20587 ¼­¿ï ´ëÇѽÅÀåÇÐȸ APCN & KSN 2024 2ÀÏÂ÷ : 2024-06-14 0 39 2024-04-29
20586 °æºÏ 2024 ´ëÇÑÆó¾ÏÇÐȸ Ãá°èÇмú´ëȸ : 2024-06-14 0 52 2024-04-29
20585 ¼­¿ï ´ëÇѽÅÀåÇÐȸ APCN & KSN 2024 1ÀÏÂ÷ : 2024-06-13 0 69 2024-04-29
20584 ¼­¿ï ´ëÇÑ°ñ´ë»çÇÐȸ SSBH 2024 (The 12th Seoul Symposium on Bone Health)&Á¦36Â÷ Ãá°èÇмú´ëȸ 1ÀÏÂ÷ : 2024-06-13 0 59 2024-04-29
20583 ¼­¿ï (¿Â¶óÀÎ)À̺ñÀÎÈÄ°ú Áö¿ªÀÇ»çÁý´ãȸ-ÃÖ½ÅÇü º¸Ã»±â¿Í ¸ÂÃãÇü º¸Ã»±â ó¹æ¿ä·É : 2024-06-13 0 51 2024-04-29
20582 ¼­¿ï °­³²¼¼ºê¶õ½º ¾È°ú Áö¿ªÀÇ»çÁý´ãȸ(³­Ä¡¼º °¢¸· Áúȯ) : 2024-06-11 0 70 2024-04-29
20581 ¼­¿ï [¿Â¶óÀÎ] Á¦274ȸ ´ëÇÑ ¼Ò¾Æ¾Ë·¹¸£±â È£Èí±âÇÐȸ ¿ù·Ê ÇмúÁý´ãȸ(Æó±â´É°ú ±â°üÁö°ú¹Î¼º) : 2024-06-11 0 46 2024-04-29
20580 ¼­¿ï °¡Å縯´ëÇб³¼­¿ï¼º¸ðº´¿ø [¿Â¶óÀÎ] Á¦ 26 ȸ ¿Ü·¡Â÷¿øÀÇ ¼Ò¾Æû¼Ò³â°ú ÀÓ»ó : 2024-06-09 0 51 2024-04-29
20579 ¼­¿ï °í·Á´ëÇб³±¸·Îº´¿ø ¼øȯ±â³»°ú 16ȸ KOALA Symposium 2024 : 2024-06-09 0 46 2024-04-29
20578 ¼­¿ï ´ëÇÑÀ̺ñÀÎÈÄ°úÀÇ»çȸ (¿Â¶óÀÎ) Á¦3ȸ ¼ö¸é°øµ¿½ÉÆ÷Áö¾ö : 2024-06-09 0 59 2024-04-29
20577 ¼­¿ï ´ëÇÑ´ç´¢º´ÇÐȸ 2024 ´ç´¢º´ °³¿øÀÇ ¿¬¼ö°­Á : 2024-06-09 0 71 2024-04-29
20576 ¼­¿ï 2024 ´ëÇѽŰæÁýÁßÄ¡·áÇÐȸ Ãá°èÇмú´ëȸ : 2024-06-08 0 63 2024-04-29
20575 ¼­¿ï 2024 »ó¹Ý±â ´ëÇÑÇ÷¾×ÇÐȸ ´Ù¹ß°ñ¼öÁ¾¿¬±¸È¸ ½ÉÆ÷Áö¾ö(2024 »ó¹Ý±â KMMWP workshop & Àӻ󿬱¸¸ðÀÓ) : 2024-06-08 0 51 2024-04-29
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷